ATAI adds MDMA biotech to growing list of psychedelic makers; Acadia adds $52.5M upfront pain buyout

June 22, 2020 Articles 7:21 pm

ATAI Life Sciences aims to transform mental health care, backing companies working on new treatments for depression, anxiety and addiction. Now, it’s adding digital tools to the mix through a new company called IntroSpect Digital Therapeutics.

JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on atai and innovations in the space.

Email
submit

JOIN THE ATAI #INSIGHTNETWORK

Sign up to receive the latest news on atai.